IA
GLUE icon

IFP Advisors’s Monte Rosa Therapeutics GLUE Stock Holding History

IFP Advisors’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.5K Sell
1,178
-17
-1% -$321 ﹤0.01% 2747
2026
Q1 		$19.7K Sell
1,195
-23
-2% -$440 ﹤0.01% 2785
2025
Q4 		$19.1K Buy
1,218
+66
+6% +$889 ﹤0.01% 2747
2025
Q3 		$8.54K Sell
1,152
-30
-3% -$159 ﹤0.01% 2987
2025
Q2 		$5.33K Buy
+1,182
New +$5.27K ﹤0.01% 3335
2025
Q1 		– Hold
0
– – – 4123
2024
Q4 		– Hold
0
– – – 4306

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

IFP Advisors's GLUE Position: Q2 2026 in Review

IFP Advisors reduced its Monte Rosa Therapeutics (GLUE) stake by 1.4% in Q2 2026, selling an estimated $321 and leaving 1,178 shares worth $28.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2747.

IFP Advisors first reported a position in GLUE in Q2 2025 and has held it in 5 quarters since. 192 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • IFP Advisors held 1,178 shares of Monte Rosa Therapeutics worth $28.5K as of Q2 2026.
  • IFP Advisors sold 17 Monte Rosa Therapeutics shares in Q2 2026, an estimated $321.
  • Monte Rosa Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #2747 holding.
  • IFP Advisors first reported a position in Monte Rosa Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 192 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.